DK200300015A - Anvendelse af stammer af Parapoxvirus ovis til fremstilling af antivirale lægemidler og lægemidler mod cancer - Google Patents
Anvendelse af stammer af Parapoxvirus ovis til fremstilling af antivirale lægemidler og lægemidler mod cancer Download PDFInfo
- Publication number
- DK200300015A DK200300015A DK200300015A DKPA200300015A DK200300015A DK 200300015 A DK200300015 A DK 200300015A DK 200300015 A DK200300015 A DK 200300015A DK PA200300015 A DKPA200300015 A DK PA200300015A DK 200300015 A DK200300015 A DK 200300015A
- Authority
- DK
- Denmark
- Prior art keywords
- strains
- manufacture
- antiviral
- drugs
- parapoxvirus ovis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
PATENTKRAV 1. Anvendelse af vira, der taxonomisk hører til en af stammerne NZ2, NZ-7, NZ-10 eller orf-11 af Parapoxvirus ovis til fremstilling af lægemidler mod virusinfektioner og cancer hos menneske og dyr. 2. Anvendelse af ved passage på eller tilpasning til egnede cellesystemer, f.eks. humane celler som WI-38-, MRC-5- og vero-celler, bovine celler som BK-KI3A47/Reg eller MDBK, og ovine celler som MDOK fremkomne efterkommere af virus ifølge krav 1 til fremstilling af lægemidler mod virusinfektioner og cancer hos menneske og dyr. 3. Anvendelse af dele eller brudstykker af viraene ifølge krav 1 og 2, idet der ved dele forstås ved hjælp af egnede vektorer, såsom vacciniavira, i egnede systemer, f.eks. fibroblastcellekulturer, eksprimerede genomiske eller subgenomiske fragmenter, og ved brudstykker forstås de ved biokemisk oprensning, såsom chromatografi, fremkomne fraktioner af de eksprimerede eller fysisk oplukkede virale partikler, til fremstilling af lægemidler mod virusinfektioner og cancer hos menneske og dyr. 4. Anvendelse af en af stammerne af Parapoxvirus ovis ifølge krav 1-3 til fremstilling af lægemidler og farmaceutiske præparater som immunterapeutika eller immun-profylaktika ved autoimmunsygdomme og ved akutte og kroniske virusinfektiner i åndedrætsorganerne og de indre organer. 5. Anvendelse af en af stammerne ifølge krav 1-3 til fremstilling af lægemidler og farmaceutiske præparater til stressmetafylakse og til forhindring eller forebyggelse af infektionssygdomme efter stress samt ved infektionsprofylakse inden for rammerne af operationer og tandlægeindgreb. 6. Anvendelse af en af stammerne ifølge krav 1-3 til fremstilling af lægemidler og farmaceutiske præparater til anvendelse ved infektionsmetafylakse eller terapi af akutte virusinfektioner, f.eks. i åndedrætsorganerne, papillomvirusinfektioner, infektion med herpesvira, HIV-infektion, virusinfektion i indre organer, f.eks. infektion med hepatitisvira, samt anvendelse ved sygdomme som dissemineret sclerose, astma, vorter og andre nydannelser på huden. 7. Anvendelse af en af stammerne ifølge krav 1-3 til fremstilling af lægemidler og farmaceutiske præparater til anvendelse på sår til fremskyndelse af sårhelingsprocesser og anvendelse til understøttelse af helingen af dårligt eller ikke helende sår og Ulcus cruris. 8. Anvendelse af en af stammerne ifølge krav 1-3 til fremstilling af lægemidler og farmaceutiske præparater til anvendelse ved sygdomme i den allergiske formkreds, psoriasis, neurodermitis, andre autoimmunsygdomme, f.eks. Lupus erythematosus, samt til forbedring af velbefindendet, f.eks. med alderen. 9. Anvendelse af en af stammerne ifølge krav 1-3 til fremstilling af lægemidler og farmaceutiske præparater til anvendelse mod inflammatoriske, degenerative og proliferative sygdomme i de indre organer (f.eks. Morbus Crohn), huden, blodet, centralnervesystemet og dets vedhængende dannelser, herunder øjet, herunder cancer. 10. Anvendelse af en af stammerne af Parapoxvirus ovis ifølge krav 1-3 i kombination med andre midler til fremstilling af lægemidler og farmaceutiske præparater til antiviral terapi eller cancerterapi hos menneske og dyr. 11. Anvendelse af en af stammerne af Parapoxvirus ovis svarende til krav 1-3 i kombination med andre midler til fremstilling af lægemidler og farmaceutiske præparater til oral indgivelse og/eller i et mavesaftresistent præparat til oral indgivelse.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10033582 | 2000-07-11 | ||
| DE10122451A DE10122451A1 (de) | 2000-07-11 | 2001-05-09 | Verwendung von Stämmen des Parapoxvirus ovis zur Herstellung von antiviralen Arzneimitteln und Arzneimitteln gegen Krebs |
| PCT/EP2001/007991 WO2002004002A2 (de) | 2000-07-11 | 2001-07-11 | Verwendung von stämmen des parapoxvirus ovis zur herstellung von antiviralen arzneimitteln und arzneimitteln gegen krebs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK200300015A true DK200300015A (da) | 2003-03-07 |
Family
ID=26006335
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01949489T DK1303286T3 (da) | 2000-07-11 | 2001-07-11 | Anvendelse af stammer af parapoxvirus ovis til fremstilling af antivirale lægemidler og lægemidler mod kræft |
| DK200300015A DK200300015A (da) | 2000-07-11 | 2003-01-10 | Anvendelse af stammer af Parapoxvirus ovis til fremstilling af antivirale lægemidler og lægemidler mod cancer |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01949489T DK1303286T3 (da) | 2000-07-11 | 2001-07-11 | Anvendelse af stammer af parapoxvirus ovis til fremstilling af antivirale lægemidler og lægemidler mod kræft |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US6685950B2 (da) |
| EP (1) | EP1303286B1 (da) |
| JP (1) | JP5037775B2 (da) |
| CN (1) | CN1455674B (da) |
| AR (1) | AR029954A1 (da) |
| AT (1) | ATE324115T1 (da) |
| AU (2) | AU7063101A (da) |
| BG (1) | BG107448A (da) |
| CA (1) | CA2415397C (da) |
| CY (1) | CY1105408T1 (da) |
| CZ (1) | CZ200371A3 (da) |
| DE (1) | DE50109630D1 (da) |
| DK (2) | DK1303286T3 (da) |
| EE (1) | EE200300018A (da) |
| ES (1) | ES2262663T3 (da) |
| FI (1) | FI20030037A (da) |
| GB (1) | GB2381454B8 (da) |
| HK (1) | HK1054329B (da) |
| HR (1) | HRP20030096A2 (da) |
| HU (1) | HUP0400479A3 (da) |
| IL (1) | IL153643A0 (da) |
| LT (1) | LT5079B (da) |
| LU (1) | LU90997B1 (da) |
| LV (1) | LV12990B (da) |
| MA (1) | MA26927A1 (da) |
| MX (1) | MXPA03000279A (da) |
| NO (1) | NO20030082D0 (da) |
| NZ (1) | NZ523534A (da) |
| PL (1) | PL366397A1 (da) |
| PT (1) | PT1303286E (da) |
| RU (1) | RU2003104525A (da) |
| SE (1) | SE0300034L (da) |
| SI (1) | SI21122A (da) |
| SK (1) | SK362003A3 (da) |
| UY (1) | UY26832A1 (da) |
| WO (1) | WO2002004002A2 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19922407A1 (de) * | 1999-05-14 | 2000-11-16 | Bayer Ag | Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus |
| US7097842B2 (en) * | 2000-11-23 | 2006-08-29 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US7628980B2 (en) * | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| EP1335987B2 (en) * | 2000-11-23 | 2016-06-15 | Bavarian Nordic A/S | Modified vaccinia ankara virus variant |
| NZ512341A (en) | 2001-06-13 | 2004-02-27 | Bayer Ag | Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments |
| EP1499355A4 (en) * | 2001-12-07 | 2005-10-05 | Bayer Pharmaceuticals Corp | USE OF PARAPOX B2L PROTEIN FOR THE TREATMENT OF CANCER AND THE MODIFICATION OF IMMUNE RESPONSES |
| IL163701A0 (en) * | 2002-04-19 | 2005-12-18 | Bavarian Nordic As | Modified vaccinia virus ankara for the vaccinationof neonates |
| UA85543C2 (ru) * | 2002-09-05 | 2009-02-10 | Бавариан Нордик А/С | Способ культивирования первичных клеток и амплификации вирусов в условиях безсывороточной среды, композиция и ее применение, и способ лечения или вакцинации животных |
| DE602005016552D1 (de) * | 2004-07-13 | 2009-10-22 | Aicuris Gmbh & Co Kg | Parapocken-viren in kombination mit anderen antiviralen mitteln zur behandlung von hiv/aids |
| ES2335308T3 (es) | 2005-11-24 | 2010-03-24 | AICURIS GMBH & CO. KG | Parapoxvirus en combinacion con agentes quimioterapeuticos clasicos como bioquimoteparia para el tratamiento del cancer. |
| JP5004990B2 (ja) * | 2009-03-31 | 2012-08-22 | アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト | パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物 |
| US9090897B2 (en) * | 2009-12-18 | 2015-07-28 | Bavarian Nordic A/S | Production of IFN-lambda by conventional dendritic cells |
| JP5699093B2 (ja) * | 2012-01-05 | 2015-04-08 | アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフトＡｉＣｕｒｉｓ ＧｍｂＨ ＆ Ｃｏ． ＫＧ | パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物 |
| TW201919675A (zh) * | 2017-09-07 | 2019-06-01 | 德商艾庫瑞斯公司 | 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法 |
| WO2023083950A1 (en) * | 2021-11-10 | 2023-05-19 | Aicuris Gmbh & Co. Kg | Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with immunomodulators |
| WO2023083943A1 (en) * | 2021-11-10 | 2023-05-19 | Aicuris Gmbh & Co. Kg | Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with antivirals |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2714665A1 (de) * | 1977-04-01 | 1978-10-05 | Mayr Anton | Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung |
| DE3504940C2 (de) * | 1984-02-17 | 1997-11-06 | Bayer Ag | Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel |
| US5443964A (en) * | 1987-08-10 | 1995-08-22 | Duke University | Poxvirus insertion/expression vector |
| DE4405841C1 (de) * | 1994-02-23 | 1995-01-05 | Mayr Anton Prof Dr Med Vet Dr | Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US5648101A (en) * | 1994-11-14 | 1997-07-15 | Tawashi; Rashad | Drug delivery of nitric oxide |
| US6365393B1 (en) * | 1996-02-28 | 2002-04-02 | Bayer Aktiengesellschaft | Parapoxviruses containing foreign DNA, their production and their use in vaccines |
| WO1997037031A1 (en) * | 1996-03-29 | 1997-10-09 | University Of Otago | Parapoxvirus vectors |
| DE19780300D2 (de) * | 1996-04-15 | 1999-06-17 | Mayr Anton Prof Dr Med Vet Dr | Neue Indikationen für die Verwendung von multipotenten Paramunitätsinducern aus attenuierten, nicht-immunogenen Pockenviren oder Parapockenvieren als Arzneitmittel |
| SE9700617D0 (sv) * | 1997-02-21 | 1997-02-21 | Kjell Alving | New composition |
| DE19843222A1 (de) * | 1998-09-22 | 2000-03-30 | Hassan Jomaa | Verwendung von phosphororganischen Verbindungen zur therapeutischen und prophylaktischen Behandlung von Infektionen |
| NZ511119A (en) * | 1998-11-02 | 2004-04-30 | Ludwig Inst Cancer Res | Vascular endothelial growth factor-like protein from ORF virus NZ2 binds and activates mammalian VEGF receptor-2 |
-
2001
- 2001-07-11 HU HU0400479A patent/HUP0400479A3/hu unknown
- 2001-07-11 GB GB0302630A patent/GB2381454B8/en not_active Expired - Fee Related
- 2001-07-11 ES ES01949489T patent/ES2262663T3/es not_active Expired - Lifetime
- 2001-07-11 US US09/903,013 patent/US6685950B2/en not_active Expired - Lifetime
- 2001-07-11 EE EEP200300018A patent/EE200300018A/xx unknown
- 2001-07-11 IL IL15364301A patent/IL153643A0/xx active IP Right Grant
- 2001-07-11 CZ CZ200371A patent/CZ200371A3/cs unknown
- 2001-07-11 SI SI200120048A patent/SI21122A/sl not_active IP Right Cessation
- 2001-07-11 PT PT01949489T patent/PT1303286E/pt unknown
- 2001-07-11 SK SK36-2003A patent/SK362003A3/sk not_active Application Discontinuation
- 2001-07-11 DE DE50109630T patent/DE50109630D1/de not_active Expired - Lifetime
- 2001-07-11 AR ARP010103292A patent/AR029954A1/es unknown
- 2001-07-11 LU LU90997A patent/LU90997B1/en active
- 2001-07-11 WO PCT/EP2001/007991 patent/WO2002004002A2/de active IP Right Grant
- 2001-07-11 JP JP2002508456A patent/JP5037775B2/ja not_active Expired - Lifetime
- 2001-07-11 AU AU7063101A patent/AU7063101A/xx active Pending
- 2001-07-11 RU RU2003104525/15A patent/RU2003104525A/ru not_active Application Discontinuation
- 2001-07-11 CN CN01812685.5A patent/CN1455674B/zh not_active Expired - Lifetime
- 2001-07-11 CA CA2415397A patent/CA2415397C/en not_active Expired - Lifetime
- 2001-07-11 AU AU2001270631A patent/AU2001270631B2/en not_active Expired - Fee Related
- 2001-07-11 UY UY26832A patent/UY26832A1/es not_active Application Discontinuation
- 2001-07-11 MX MXPA03000279A patent/MXPA03000279A/es unknown
- 2001-07-11 NZ NZ523534A patent/NZ523534A/en not_active IP Right Cessation
- 2001-07-11 PL PL01366397A patent/PL366397A1/xx not_active Application Discontinuation
- 2001-07-11 AT AT01949489T patent/ATE324115T1/de active
- 2001-07-11 DK DK01949489T patent/DK1303286T3/da active
- 2001-07-11 EP EP01949489A patent/EP1303286B1/de not_active Expired - Lifetime
-
2003
- 2003-01-08 BG BG107448A patent/BG107448A/bg unknown
- 2003-01-08 NO NO20030082A patent/NO20030082D0/no unknown
- 2003-01-10 SE SE0300034A patent/SE0300034L/xx not_active Application Discontinuation
- 2003-01-10 MA MA26994A patent/MA26927A1/fr unknown
- 2003-01-10 FI FI20030037A patent/FI20030037A/fi not_active IP Right Cessation
- 2003-01-10 DK DK200300015A patent/DK200300015A/da not_active Application Discontinuation
- 2003-02-03 LT LT2003009A patent/LT5079B/lt not_active IP Right Cessation
- 2003-02-10 HR HR20030096A patent/HRP20030096A2/xx not_active Application Discontinuation
- 2003-02-11 LV LVP-03-14A patent/LV12990B/lv unknown
- 2003-09-15 HK HK03106613.1A patent/HK1054329B/zh not_active IP Right Cessation
-
2006
- 2006-07-24 CY CY20061101024T patent/CY1105408T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK200300015A (da) | Anvendelse af stammer af Parapoxvirus ovis til fremstilling af antivirale lægemidler og lægemidler mod cancer | |
| Neuzil et al. | Protective role of TNF-α in respiratory syncytial virus infection in vitro and in vivo | |
| BR0309339A (pt) | Vìrus vaccinia modificado ankara para a vacinação de neonatos | |
| RU2007141402A (ru) | Способы лечения астмы, осложненной инфекционными заболеваниями | |
| LU92311I2 (fr) | Virus de la vaccine ankara vivant modifié | |
| NZ235244A (en) | 2'-deoxy-2'-fluoro-ribonucleosides and compositions for the treatment of viral and parasitic diseases | |
| WO2008024843A3 (en) | Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein | |
| SG170825A1 (en) | Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | |
| Lin et al. | Anti-viral activity of water extract of Paeonia lactiflora pallas against human respiratory syncytial virus in human respiratory tract cell lines | |
| JP2004517807A5 (da) | ||
| MX2021010834A (es) | Compuesto y metodo para la prevencion de transmision del virus de influenza. | |
| NO20055512L (no) | Terapi eller prevensjon av respiratoriske, virale infeksjoner med alfa-tyimosinpeptider | |
| DK1765370T3 (da) | Parapox-vira i kombination med andre antivirale midler til behandling af HIV/AIDS | |
| DE3579617D1 (de) | Lebender gereinigter impfstoff gegen die marek'sche krankheit. | |
| KR101209141B1 (ko) | 독성약화된 토끼 믹소마바이러스를 기본으로 한모노파라뮤니티 유발인자 | |
| Widowati et al. | Allogeneic mesenchymal stem cells and its conditioned medium as a potential adjuvant therapy for COVID-19 | |
| Yan et al. | Antiviral activity of a cloned peptide RC28 isolated from the higher basidiomycetes mushroom Rozites caperata in a mouse model of HSV-1 keratitis | |
| DK200300014A (da) | Anvendelse af stammer af Parapoxvirus ovis mod organfibroser | |
| CA2251690C (en) | New indications for the use as medicaments of multipotent parapox immunity inducers from attenuated, non-immunogenic pox viruses or parapox viruses | |
| WO2021178582A3 (en) | Systems and methods for treating patients infected with sars-cov-2 | |
| Sawikr | Transmission and pathogenesis of Coronavirus Disease (COVID-19) outbreak | |
| Karunatilake et al. | Lack of granuloma formation in tuberculous lymphadenitis-clue to the diagnosis of human immunodeficiency virus infection | |
| CN104056268A (zh) | 一种具有抗人乳头瘤病毒及子宫内膜炎症的新型制剂 | |
| RU2175555C2 (ru) | Способ получения вируса-индуктора интерферона | |
| WO2022075955A1 (en) | Covid-19 virus vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AHS | Application shelved for other reasons than non-payment |